Document Detail


Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature.
MedLine Citation:
PMID:  20884114     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
CONTEXT: The number and location of biopsy cores and the interpretation of prostate biopsy in different clinical settings remain the subjects of continuing debate.
OBJECTIVE: Our aim was to review the current evidence regarding the performance and interpretation of initial, repeat, and saturation prostatic biopsy.
EVIDENCE ACQUISITION: A comprehensive Medline search was performed using the Medical Subject Heading search terms prostate biopsy, prostate cancer, detection, transrectal ultrasound (TRUS), nomogram, and diagnosis. Results were restricted to the English language, with preference given to those published within the last 3 yr.
EVIDENCE SYNTHESIS: At initial biopsy, a minimum of 10 but not >18 systematic cores are recommended, with 14-18 cores in glands ≥50cm(3). Biopsies should be directed laterally, and transition zone (TZ) cores are not recommended in the initial biopsy setting. Further biopsy sets, either as an extended repeat or as a saturation biopsy (≥20 cores) including the TZ, are warranted in young and fit men with a persistent suspicion of prostate cancer. An immediate repeat biopsy is not indicated for prior high-grade prostatic intraepithelial neoplasia diagnosis given an adequate extended initial biopsy. Conversely, biopsies with atypical glands that are suspicious but not diagnostic of cancer should be repeated within 3-6 mo. Overall recommendations for further biopsy sets (a third set or more) cannot be made. Transrectal ultrasound-guided systematic biopsies represent the standard-of-care method of prostate sampling. However, transperineal biopsies are an up-to-standard alternative.
CONCLUSIONS: The optimal prostatic biopsy regimen should be based on the individualized clinical setting of the patient and should follow the minimum standard requirements reported in this paper.
Authors:
Felix K-H Chun; Jonathan I Epstein; Vincenzo Ficarra; Stephen J Freedland; Rodolfo Montironi; Francesco Montorsi; Shahrokh F Shariat; Fritz H Schröder; Vincenzo Scattoni
Related Documents :
17308874 - Transrectal ultrasound guided biopsy for detecting prostate cancer: can random biopsies...
2025884 - Monoclonal antibody 323/a3: a marker for the presence of breast carcinoma.
21544804 - Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and...
9915434 - Comparison of digital rectal examination and biopsy results with the radical prostatect...
12165804 - Population-based screening for hereditary breast cancer in a region of north-central it...
7742004 - Genetic changes in ovarian cancer.
Publication Detail:
Type:  Journal Article     Date:  2010-09-04
Journal Detail:
Title:  European urology     Volume:  58     ISSN:  1873-7560     ISO Abbreviation:  Eur. Urol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2011-03-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7512719     Medline TA:  Eur Urol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  851-64     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 European Association of Urology. All rights reserved.
Affiliation:
Department of Urology, University Hospital Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  More is not always better: coping with ambiguity in natural resources management.
Next Document:  Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal...